ERBB2 and cancer: Sub‐grouping indicated that the effect on survival was confined to ER−/HER2+ cancers (n = 31; p = 0.006), with no statistically significant associations in patients with ER+/HER2− or ER+/HER2+ tumours (Figure 2).